PPI Use Ups Risk of Osteoporosis, Osteopenia in Femur

This article originally appeared here.
Share this content:
PPI Use Ups Risk of Osteoporosis, Osteopenia in Femur
PPI Use Ups Risk of Osteoporosis, Osteopenia in Femur

WEDNESDAY, June 8, 2016 (HealthDay News) -- Proton pump inhibitor (PPI) use is associated with increased risk of developing osteoporosis and osteopenia in femur bones, according to a study published online May 31 in the International Journal of Rheumatic Diseases.

Abbas Arj, M.D., from the Kashan University of Medical Sciences in Iran, and colleagues examined the correlation between PPI use and bone mineral density (BMD) in a cross-sectional study involving 80 patients (40 PPI users and 40 PPI non-users) without history of hip fracture. Dual-energy X-ray absorptiometry was performed to quantify femur and posterior-anterior spine BMD in all participants.

The researchers observed significant differences in the mean femoral T-scores for the PPI-user and non-user groups (−0.44 ± 1.11 and 0.19 ± 0.95, respectively; P = 0.007). The exposed group also had significantly greater frequency of femoral osteoporosis and osteopenia than the control group (P = 0.04). No significant between-group difference was noted in mean femoral Z-scores, lumbar spine T-score, or lumbar spine Z-score. In linear regression analysis, no correlation was seen for PPI users and non-users with lumbar spine T-score.

"Overall, the results of this study showed that PPI use in subjects without risk factors of osteoporosis determined by the femoral T-score compared with the control group was associated with increased risk of developing osteoporosis and osteopenia in the femur bones," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »